Clinical and Financial Burden of Mental Health Conditions in Patients with Low-Grade Non-Hodgkin Lymphoma

Keri Yang,¹ Kaitlyn Esselman,² Po-Ya Chuang,² Wesley Furnback,² Asher Chanan-Khan³

¹BeiGene, San Mateo, CA, USD; ²Real Chemistry, New York, NY, USA; ³Mayo Clinic, Tampa, FL, USA

INTRODUCTION

- Low-grade non-Hodgkin lymphoma (LG-NHL) encompasses a number of cancers including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL)
- LG-NHL is often incurable, imposing a prolonged impact of cancer care burden for patients

OBJECTIVES

 This study aimed to quantify the clinical and economic burden of mental health (MH) conditions in patients with newly diagnosed CLL/SLL, FL, MCL, WM, or MZL in the US

METHODS

Data Source

• The study was conducted using Optum® Clinformatics® Data Mart, a comprehensive, longitudinal, closed-claims database

Inclusion Criteria

- Patients aged ≥18 years with ≥1 first diagnosis of CLL/SLL, FL, MCL, WM, or MZL were included
- The study period was from May 1, 2016 to June 30, 2023 with an index period of June 30, 2016 to June 30, 2022
- The index date was the date of first cancer diagnosis
- Eligible patients had continuous enrollment in the database for 60 days prior to and 365 days after the index date
- Patients were followed for a minimum of 365 days through loss to follow-up or end of the study period (June 30, 2023)

Mental Health Conditions

- MH conditions of interest included:
- Anxiety
- Depression
- Stress reaction/adjustment disorder
- Insomnia
- Post-traumatic stress disorder (PTSD)
- Prevalence and incidence of MH conditions were categorized based on if MH condition diagnoses were before or after the index date
- Baseline demographics, healthcare resource utilization (outpatient visits and inpatient admissions) and total cost of care (costs incurred from outpatient visits, inpatient admissions, emergency room visits, pharmacy, and other/ ancillary services) were measured for LG-NHL patients with prevalent or incident MH

RESULTS

Patients (Table 1)

• 36,054 patients were newly diagnosed with one of the cancers of interest, LG-NHL, during the index period

Table 1. Patient Demographics


Characteristic	CLL/SLL	FL	MCL	WM	MZL
N	19,891	9,715	1,728	1,738	2,982
Age, mean (SD)	71.9 (10.2)	69.3 (11.8)	71.1 (10.4)	74.0 (9.5)	69.7 (11.9)
Sex, % male	54.5	48.0	65.5	56.0	41.6
Race (%)					
Asian	2.0	2.8	2.1	3.3	3.2
Black	7.9	7.7	6.7	8.2	9.7
White	84.4	83.3	85.5	84.3	81.4
Missing/unknown	6.2	6.2	5.7	4.2	5.7
Ethnicity,					
% Non-Hispanic	90.7	90.7	92.1	93.2	90.1

CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; MCL, mantle zone lymphoma; MZL, marginal zone lymphoma; SD, standard deviation;

Rates of MH Conditions (Figure 1)

- Approximately half (48.0%-57.2%) of patients had either a prevalent or incident MH condition during the study period
- Median time from cancer diagnosis to onset of any MH condition was 334 days for CLL/SLL, 301 for FL, 248 for MCL, 351 for WM, and 328 for MZL
- Anxiety and depression were the most frequently diagnosed MH conditions, affecting 30.9% to 39.2% and 27.5% to 31.9% of patients, respectively (Figures 2 and 3)

Figure 1. Rates of Any Prevalent or Incident MH Condition by Cancer Type



CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; MCL, mantle zone lymphoma; MH, mental health; MZL, marginal zone lymphoma; SLL, small lymphocytic lymphoma; WM, Waldenström macroglobulinemia.

Figure 2. Rates of Incident MH Conditions by Cancer Type





Figure 3. Rates of Prevalent MH Conditions by Cancer Type




CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; MCL, mantle cell lymphoma; MH, mental health; MZL, marginal zone lymphoma; PTSD, post-traumatic stress disorder; SLL, small lymphocytic lymphoma; WM, Waldenström macroglobulinemia.

Healthcare Resource Utilization


- The mean number of outpatient visits within the year after a cancer diagnosis
 was statistically higher, ranging from 1.3 to 1.4 times more, among those with a
 MH diagnosis compared to those without (Figure 4)
- Mean inpatient admissions were statistically higher (2.0 to 2.6 times) in those with MH conditions compared to those without (**Figure 5**)

Figure 4. Mean Outpatient Visits Among Patients With and Without



CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; MCL, mantle cell lymphoma; MH, mental health; MZL, marginal zone lymphoma; SLL, small lymphocytic lymphoma; WM, Waldenström macroglobulinemia.

Figure 5. Mean Inpatient Admissions Among Patients With and Without MH Diagnoses



CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; MCL, mantle cell lymphoma; MH, mental health; MZL, marginal zone lymphoma; SLL, small lymphocytic lymphoma; WM, Waldenström macroglobulinemia.


CONCLUSIONS

- This real-world study uncovered a high proportion of LG-NHL patients suffer from MH conditions, incurring higher financial burden than those without
- With advancements in new treatments, there remains unmet need of MH burden in these patients

Total Cost of Care

• Total costs of care in the one-year post cancer diagnosis were statistically higher (1.4 to 1.7 times) for those with an MH condition (**Figure 6**)

Figure 6. Total Cost of Care Among Patients With and Without MH Diagnoses (one-year post-cancer diagnosis)




CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; MCL, mantle cell lymphoma; MH, mental health; MZL, marginal zone lymphoma; SLL, small lymphocytic lymphoma; WM, Waldenström macroglobulinemia.

DISCUSSION

- The study is observational in nature and can only suggest associations, not establish causation
- The post-index inclusion criteria of continuous enrollment of 365 days may have potentially excluded otherwise eligible patients from the study and hence, the results may be under-reported

ACKNOWLEDGMENTS

• This study was sponsored by BeiGene, Ltd.



Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ASCO® or the author of this poster.